All News

One for you, one for me! So many pasalubong char @RHEUMarampa @RheumNow #acr23 #ACRambassador https://t.co/v0mZ9vbadx

Links:

Lisa 🐳🗺🧭 rheumarhyme ( View Tweet)
Cellular based biology explanation of sex bias in ARDs 👀 Data from AMP w/ sc-RNA seq from synovial tissue shows: Enriched inflammatory pathways in females synovial macrophages clusters vs. males Basis for gender specific treatment strategies? @RheumNow ABST0724 #ACR23 https://t.co/1p8PDIRNoI
Aurelie Najm  ( View Tweet)
Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE
Robert B Chao, MD  ( View Tweet)
In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH ✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis ✳️TRAF5 overexpression attenuated PAH sxs in mice TRAF5 as potential BM for dx/novel tx target in SLE-PAH? #ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s
sheila  ( View Tweet)
Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok
Mike Putman EBRheum ( View Tweet)
Abst#0725 #ACR23 @RheumNow PEXIVAS Real life data! GPA & MPA pts - Retrosp observ study ⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx ⚠️Caution w/ reduced GC, RTX, severe kidney dis #ACRBest https://t.co/7qI5c1ZiqO
Eric Dein  ( View Tweet)
Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants have more aggressive renal and vascular disease. #DuboisLecture #ACR23 #StrongWomen #FutureNobelRecipient https://t.co/IzRsHwaMIb
TheDaoIndex KDAO2011 ( View Tweet)
Interesting study on PEXIVAS reduced steroid use from today's plenary session! Reduced steroid dose in GPA/MPA pts associated w/ INCREASED risk of death, ESKD, progression of dz Even greater risk in pts with higher Cr lvls or RTX induction use @RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
Robert B Chao, MD  ( View Tweet)
In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs Further prospective studies req'd? BEL remains an option for non-renal SLE tx. #ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk
sheila  ( View Tweet)
Did you know? 👉APOL1 variants are protective against trypanosomiasis. 👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had: ⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ
TheDaoIndex KDAO2011 ( View Tweet)
Abs#0726 #ACR23 @RheumNow MSUS recs in Canadian Rheum training 🇨🇦: Focus MSUS exam of hands/wrists/feet: ID effusion, synov, erosions v osteophyte, tenosyn Limited MSUS of knee/ankle for effusion @USSONAR_Rh @MymaAlbaydaMD Agree: MSUS should be part of rheum training for all https://t.co/UNPpAA1p0V
Eric Dein  ( View Tweet)
Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB
Richard Conway  ( View Tweet)
Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ #RheumEd #POCUS https://t.co/mqdcPEeMYW
Janet Pope  ( View Tweet)
INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a
Richard Conway  ( View Tweet)
Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23

Janet Pope  ( View Tweet)

A good clinical trial should consist of not denying a standard of care comparator. Difficult to enrol in protocols requiring placebo in active disease. Maybe learn from #ped #rheum #RCTs where all get active #Rx then randomized to stop vs continue&trial designs. @RheumNow #ACR23 https://t.co/eQFEktsfBt

Janet Pope  ( View Tweet)

A woman who knows how to integrate fashion into science. @ashira_md noted how TLR’s look like the Chanel brand @CHANEL #ACr23 @RheumNow @uptoTate @AWIRGROUP @gwenesta_melton #ScienceIsCool https://t.co/GQro9xR71W
TheDaoIndex KDAO2011 ( View Tweet)
SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE: ⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS Key message? Addt'l tx needed to avoid high GC doses #ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S
sheila  ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

CV events in women w/ ARDs pregnancies: -2.0% of 19,340 pregnant ARDs Adjusted relative risk: -4 fold in ARD -15 fold in primary APS -6 fold in SLE -SLE + APS 18 fold 25-30% occur in early post partum! Need for continued vigilance after delivery @RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB
Aurelie Najm  ( View Tweet)
×